TY - JOUR
T1 - From the hypotheses to clinical evidence in retinal therapy
AU - Beatson, Bradley
AU - Arevalo, Fernando
N1 - Publisher Copyright:
© 2021 JOURNAL OF OPHTHALMIC AND VISION RESEARCH | PUBLISHED BY KNOWLEDGE E.
PY - 2021/4
Y1 - 2021/4
N2 - The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization and slow progression of disease. Here, we will review the literature and investigative developments on the use of IVB as a preoperative adjuvant to vitrectomy in severe PDR, specifically focusing on its ability to reduce intra- A nd postoperative complications and its risk for progression or development of traction retinal detachment.
AB - The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization and slow progression of disease. Here, we will review the literature and investigative developments on the use of IVB as a preoperative adjuvant to vitrectomy in severe PDR, specifically focusing on its ability to reduce intra- A nd postoperative complications and its risk for progression or development of traction retinal detachment.
KW - Diabetic macular edema
KW - Diabetic retinopathy
KW - Intravitreal bevacizumab
KW - Tractional retinal detachment
KW - Vascular endothelial growth factor
KW - Vitrectomy
UR - http://www.scopus.com/inward/record.url?scp=85106728930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106728930&partnerID=8YFLogxK
U2 - 10.18502/jovr.v16i2.9092
DO - 10.18502/jovr.v16i2.9092
M3 - Review article
C2 - 34055265
AN - SCOPUS:85106728930
SN - 2008-2010
VL - 16
SP - 287
EP - 290
JO - Journal of Ophthalmic and Vision Research
JF - Journal of Ophthalmic and Vision Research
IS - 2
ER -